These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN; J Hepatol; 2023 Dec; 79(6):1542-1556. PubMed ID: 37364790 [TBL] [Abstract][Full Text] [Related]
7. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Lazarus JV; Newsome PN; Francque SM; Kanwal F; Terrault NA; Rinella ME Hepatology; 2024 Mar; 79(3):E93-E94. PubMed ID: 37983810 [No Abstract] [Full Text] [Related]
8. The new hepatic steatosis nomenclature. No more NAFLD! Castro-Narro GE; Rinella ME Rev Gastroenterol Mex (Engl Ed); 2024; 89(2):312-313. PubMed ID: 38789309 [No Abstract] [Full Text] [Related]
9. Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hoofnagle JH; Doo E Hepatology; 2024 Mar; 79(3):E91-E92. PubMed ID: 37983836 [No Abstract] [Full Text] [Related]
10. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Narro GEC; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN; Ann Hepatol; 2024; 29(1):101133. PubMed ID: 37364816 [TBL] [Abstract][Full Text] [Related]
11. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN; Hepatology; 2023 Dec; 78(6):1966-1986. PubMed ID: 37363821 [TBL] [Abstract][Full Text] [Related]
12. Reclassification of nonalcoholic fatty liver disease: a multi-society Delphi consensus statement. Bajo FR; Shipman KE Clin Exp Dermatol; 2023 Nov; 48(12):1418-1421. PubMed ID: 37616524 [No Abstract] [Full Text] [Related]
13. Toward More Accurate Nomenclature for Fatty Liver Diseases. Eslam M; Sanyal AJ; George J Gastroenterology; 2019 Sep; 157(3):590-593. PubMed ID: 31158374 [No Abstract] [Full Text] [Related]
14. Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice. Brennan PN; Tavabie OD; Li W; Marjot T; Corless L; Fallowfield JA; Jarvis H; Mansour D; McPherson S; Rosenberg W; Rockell K; Tomlinson J; Yeoman A; Tsochatzis EA; Dillon JF; Alazawi W; Abeysekera KWM Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):577-582. PubMed ID: 38428439 [TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: Conceptual changes for clinicians, researchers and patients. Lin SZ; Chen YW; Fan JG J Dig Dis; 2020 Nov; 21(11):604-609. PubMed ID: 32975050 [TBL] [Abstract][Full Text] [Related]
16. Impact of new fatty liver disease nomenclature on primary care- cerebration of gastroenterologists in a regional tertiary care hospital. Chen X; Liu D; Li R Ann Hepatol; 2024; 29(3):101486. PubMed ID: 38403069 [No Abstract] [Full Text] [Related]
17. [NASH: new terminology and what else is new in 2020]. Spahr L; Giostra E; Negro F; Goossens N Rev Med Suisse; 2020 Sep; 16(704):1544-1547. PubMed ID: 32880109 [TBL] [Abstract][Full Text] [Related]
19. Is it time to change NAFLD and NASH nomenclature? Bellentani S; Tiribelli C Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):547-548. PubMed ID: 28691681 [No Abstract] [Full Text] [Related]
20. From NAFLD to MASLD: Promise and pitfalls of a new definition. Cusi K; Younossi Z; Roden M J Hepatol; 2024 Jul; 81(1):e18-e19. PubMed ID: 38906626 [No Abstract] [Full Text] [Related] [Next] [New Search]